SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1998
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from ____ to ____
Commission file number 0-13634
MACROCHEM CORPORATION
(Exact name of registrant as
specified in its charter)
DELAWARE 04-2744744
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Organization) Identification Number)
110 HARTWELL AVENUE, LEXINGTON, MASSACHUSETTS 02421-3134
(Address of principal executive offices, Zip Code)
(781) 862-4003
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- -----
As of September 30, 1998, there were 22,138,879 shares of Common Stock,
$.01 par value per share, of the Registrant outstanding.
<PAGE>
MACROCHEM CORPORATION
INDEX
PAGE NUMBER
PART I Financial Information
Item 1 Unaudited Financial Statements
Unaudited Balance Sheets
September 30, 1998 and December 31, 1997 3-4
Unaudited Statements of Operations
Three Months and Nine Months Ended
September 30, 1998 and 1997 5
Unaudited Statements of Cash Flows
Nine Months Ended September 30, 1998 and 1997 6-7
Notes to Unaudited Financial Statements 8
Item 2 Management's Discussion and Analysis of
Financial Condition and Results of Operations 9-12
PART II Other Information
Item 6 Exhibits and Reports on Form 8-K 13
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1. UNAUDITED FINANCIAL STATEMENTS
MACROCHEM CORPORATION
UNAUDITED BALANCE SHEETS
ASSETS
September 30, December 31,
1998 1997
------------- ------------
CURRENT ASSETS:
Cash and cash equivalents $ 6,169,583 $24,952,121
Marketable securities 15,927,391 ---
Accounts receivable 187,497 ---
Prepaid expenses and other
current assets 176,060 117,683
---------- ----------
TOTAL CURRENT ASSETS 22,460,531 25,069,804
---------- ----------
PROPERTY AND EQUIPMENT,
net of accumulated depreciation:
1998-$687,169; 1997-$582,769 398,122 281,216
---------- ----------
OTHER ASSETS:
Patents, net of accumulated
amortization: 1998-$ 75,218;
1997-$59,603 311,459 268,356
Deposits 4,460 4,460
---------- ----------
TOTAL ASSETS $23,174,572 $25,623,836
========== ==========
(Continued)
<PAGE>
MACROCHEM CORPORATION
UNAUDITED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' EQUITY
September 30, December 31,
1998 1997
------------- ------------
CURRENT LIABILITIES:
Capitalized lease obligations $ 4,813 $ 18,408
Accounts payable and accrued
expenses 651,317 204,352
Deferred compensation and
related accrued interest 92,916 90,140
---------- ----------
TOTAL CURRENT LIABILITIES 749,046 312,900
---------- ----------
DEFERRED REVENUES 500,000 ---
---------- ----------
TOTAL LIABILITIES 1,249,046 312,900
---------- ----------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock --- ---
Common stock, $.01 par value;
authorized 60,000,000 shares;
issued 22,275,245 shares,
outstanding 22,138,879
shares at September 30, 1998
and issued and outstanding
22,182,865 shares at
December 31, 1997 222,752 221,829
Additional paid-in capital 47,243,839 46,923,677
Unearned compensation ( 183,466) ( 169,322)
Accumulated deficit (24,705,114) (21,665,248)
---------- ----------
Total paid in capital and
accumulated deficit 22,578,011 25,310,936
Less cost of treasury stock
(136,366 shares) ( 652,485) ---
---------- ----------
TOTAL STOCKHOLDERS' EQUITY 21,925,526 25,310,936
---------- ----------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 23,174,572 $ 25,623,836
========== ==========
The accompanying notes are an integral part of these unaudited financial
statements.
(Concluded)
<PAGE>
<TABLE>
MACROCHEM CORPORATION
UNAUDITED STATEMENTS OF OPERATIONS
<CAPTION>
For the three months For the nine months
ended September 30, ended September 30,
--------------------------- ---------------------------
1998 1997 1998 1997
---- ---- ---- ----
<S> <C> <C> <C> <C>
REVENUES:
Research contracts $ --- $ --- $ --- $ 50,000
Product sales --- --- --- 650
--------- ---------- ---------- ----------
TOTAL REVENUES --- --- --- 50,650
--------- ---------- ---------- ----------
OPERATING EXPENSES:
Marketing, general and
administrative 479,664 621,310 1,433,904 1,501,218
Research and development 758,232 465,748 2,479,768 1,634,269
Consulting fees with related
parties 12,000 12,000 36,000 18,000
---------- ---------- ---------- ----------
TOTAL OPERATING EXPENSES 1,249,896 1,099,058 3,949,672 3,153,487
---------- ---------- ---------- ----------
LOSS FROM OPERATIONS ( 1,249,896) ( 1,099,058) ( 3,949,672) ( 3,102,837)
---------- ---------- ---------- ----------
OTHER INCOME (EXPENSE):
Interest income 307,983 81,950 913,728 273,368
Interest expense ( 890) ( 1,679) ( 3,921) ( 5,824)
---------- ---------- ---------- ----------
TOTAL OTHER INCOME 307,093 80,271 909,807 267,544
---------- ---------- ---------- ----------
NET LOSS $( 942,803) $( 1,018,787) $( 3,039,865) $( 2,835,293)
========== ========== ========== ==========
BASIC AND DILUTED
NET LOSS PER SHARE $( 0.04) $( 0.06) $( 0.14) $( 0.18)
========== ========== ========== ==========
SHARES USED TO COMPUTE
BASIC AND DILUTED NET
LOSS PER SHARE 22,248,985 16,258,298 22,206,531 16,015,447
========== ========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these unaudited financial
statements.
<PAGE>
MACROCHEM CORPORATION
UNAUDITED STATEMENTS OF CASH FLOWS
For The Nine Months
Ended September 30,
-----------------------------
1998 1997
---- ----
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss $( 3,039,865) $( 2,835,293)
---------- ----------
Adjustments to reconcile net loss to net cash
used by operating activities:
Depreciation and amortization 132,991 92,800
Stock-based compensation 92,683 402,507
Loss on disposal of equipment --- 1,900
Amortization of discounts on
marketable securities ( 309,243) ( 176)
Retirement plan contribution in
common shares 22,306 ---
Increase (decrease) in cash from:
Accounts receivable ( 187,497) 43,977
Prepaid expenses and other current assets ( 58,377) ( 75,797)
Accounts payable and accrued expenses 446,965 ( 11,983)
Deferred compensation and related accrued
interest 2,776 1,994
Deferred rent --- ( 1,014)
Deferred revenues 500,000 34,850
---------- ----------
Total adjustments 642,604 489,058
---------- ----------
Net cash used by operating activities ( 2,397,261) ( 2,346,235)
---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of marketable securities (37,125,148) ---
Proceeds from maturities of
marketable securities 21,507,000 22,000
Expenditures for property and equipment ( 234,283) ( 27,490)
Additions to patents ( 58,717) ( 45,451)
---------- ----------
Net cash used for investing activities (15,911,148) ( 50,941)
---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital lease ( 13,595) ( 28,721)
Repurchase of common shares ( 668,494) ---
Proceeds from issuance of common stock --- 410
Proceeds from exercise of common stock options 169,432 238,627
Proceeds from exercise of common stock warrants 38,528 624,300
Proceeds from exercise of unit purchase options --- 525,000
---------- ----------
Net cash provided from financing activities ( 474,129) 1,359,616
---------- ----------
(Continued)
<PAGE>
MACROCHEM CORPORATION
UNAUDITED STATEMENTS OF CASH FLOWS
(Continued)
For The Nine Months Ended September 30,
---------------------------------------
1998 1997
---- ----
NET INCREASE (DECREASE) IN CASH
AND CASH EQUIVALENTS $(18,782,538) $(1,037,560)
CASH AND CASH EQUIVALENTS,
BEGINNING OF PERIOD 24,952,121 7,329,881
---------- ---------
CASH AND CASH EQUIVALENTS,
END OF PERIOD $ 6,169,583 $ 6,292,321
========== =========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
During the nine months ended September 30, 1998 and 1997, cash paid for interest
aggregated $1,145 and $3,830, respectively.
The Company did not pay any income taxes during those periods.
The accompanying notes are an integral part of these unaudited financial
statements.
(Concluded)
<PAGE>
MACROCHEM CORPORATION
NOTES TO UNAUDITED FINANCIAL STATEMENTS
(1) As permitted by the rules of the Securities and Exchange Commission
(the "Commission") applicable to quarterly reports on Form 10-Q, these
notes are condensed and do not contain all disclosures required by
generally accepted accounting principles. Reference should be made to
the financial statements and related notes included in the Company's
Annual Report on Form 10-K for the year ended December 31, 1997.
In the opinion of management of the Company, the accompanying unaudited
financial statements reflect all adjustments which were of a normal
recurring nature necessary for a fair presentation of the Company's
financial position, results of operations and cash flows for the three
and nine months ended September 30, 1998 and 1997.
The results disclosed in the Unaudited Statements of Operations for the
three and nine months ended September 30, 1998 are not necessarily
indicative of the results to be expected for the full year.
(2) Certain prior year amounts have been reclassified to conform to the
current presentation.
(3) In March 1997, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 128, "Earnings Per
Share", which is effective for periods ending after December 15, 1997.
SFAS No. 128 requires the Company to restate amounts previously
reported as earnings per share to comply with the requirements of SFAS
No. 128. The Company has determined that the adoption of SFAS No. 128
has had no effect on previously reported earnings per share since the
results would be anti-dilutive.
(4) The Company granted 526,000 common stock options under the 1994 Equity
Incentive Plan during the nine months ended September 30, 1998. During
this same period, 62,000 options under the 1984 Non-Qualified Stock
Option Plan, and 23,683 options under the 1994 Equity Incentive Plan
were exercised. In addition, during this period, 43,500 options under
the 1994 Equity Incentive Plan were canceled. All options were granted
with an exercise price at the fair market value of the underlying
common stock determined on the date of grant.
(5) In March 1998, the Company adopted Statement of Financial Accounting
Standards No. 130, "Reporting Comprehensive Income." The Company has
determined that the adoption of SFAS No. 130 has no effect on the
accompanying financial statements.
(6) Marketable securities are carried at cost and it is the Company's
intention to hold these short term securities to maturity.
(7) The Company adopted a 401(k) retirement plan during the three months
ended September 30, 1998. This retirement plan includes a
Company-provided match of up to 50% of the individual employee's
contributions. This matching contribution is made in common stock of
the Company. During the three months ended September 30, 1998, the
Company matching contribution amounted to approximately $22,000 and is
recorded as an expense in the statement of operations.
<PAGE>
(8) During the three months ended September 30, 1998, the Company's board
of directors approved a common share repurchase program covering up to
1,000,000 shares of common stock. The common shares acquired are
reported as treasury stock on the accompanying unaudited balance sheet.
As of October 8, 1998, the Company had acquired 154,850 common shares
at a cost of approximately $760,000.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
GENERAL
MacroChem Corporation's primary business is the development of
pharmaceutical products for commercialization by applying SEPA(R) (Soft Enhancer
of Percutaneous Absorption), its patented topical drug delivery technology. SEPA
compounds, when properly combined with drugs, provide pharmaceutical
formulations (creams, gels, solutions, etc.) that enhance the transdermal
delivery of drugs into the skin or into the bloodstream. The Company currently
derives no revenue from product sales, royalties or license fees. The Company
plans to develop specific SEPA formulations for use with proprietary and
non-proprietary drugs manufactured by pharmaceutical companies, and to
commercialize these products through the formation of partnerships, strategic
alliances and license agreements with those companies. In order to attract
strategic partners, the Company is conducting clinical testing of certain
SEPA-enhanced drugs.
The Company's results of operations vary significantly from year to
year and quarter to quarter, and depend, among other factors, on the signing of
new licenses and product development agreements, the timing of revenues
recognized pursuant to license agreements, the achievement of milestones by
licensees, the progress of clinical trials conducted by the licensees and the
Company and the degree of research, marketing and administrative effort. The
timing of the Company's revenues may not match the timing of the Company's
associated product development expenses. To date, research and development
expenses have generally exceeded revenue in any particular period and/or fiscal
year.
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO THREE MONTHS ENDED
SEPTEMBER, 1997
The Company had no revenues in the three months ended September 30,
1998 and 1997.
Marketing, general and administrative expenses decreased approximately
$142,000 (23%) primarily due to a decrease in stock compensation expense of
approximately $260,000 which was partially offset by increased consulting fees
of approximately $90,000.
Research and development expenses increased approximately $292,000
(63%) over the comparable 1997 period. Increased toxicological and clinical
trial efforts and costs related to the hiring of key research and regulatory
affairs executives accounted for most of this increase over 1997.
Other income increased approximately $227,000, resulting primarily from
interest income earned on increased cash and marketable securities.
NINE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO NINE MONTHS ENDED
SEPTEMBER 30, 1997
The Company had no revenue during the nine months ended September 30,
1998 compared to revenues of $50,650 for the nine months ended September 30,
1997.
Marketing, general and administrative expenses decreased approximately
$67,000 (4%) from the comparable 1997 period. A decrease in stock compensation
expense of approximately $288,000 was partially offset by increased compensation
and recruiting expenses and expenses associated with listing the of the
Company's common stock on the NASDAQ National Market.
Research and development expenses increased approximately $845,000
(52%) over the comparable 1997 period. Increased toxicological studies and
clinical trial efforts and costs related to the hiring of key research and
regulatory affairs executives accounted for most of this increase over 1997.
Other income increased approximately $642,000, resulting primarily from
interest income earned on increased cash and marketable securities.
YEAR 2000 COMPLIANCE
Many existing computer programs use only two digits, rather than four,
to represent a year. The Year 2000 ("Y2K") problem arises because date-sensitive
software or hardware written or developed in this fashion may not be able to
distinguish between 1900 and 2000, and programs written in this manner that
perform arithmetic operations, comparisons or sorting of date fields may yield
incorrect results when processing a Y2K date. The Y2K problem could potentially
cause system failures or miscalculations that could disrupt operations.
The Company has appointed a Director of Year 2000 Compliance who, along
with an outside Y2K consultant, is currently performing a review, which includes
testing, of the Company's computer systems. The Company believes that this
survey of financial and information technology systems will be completed in the
fourth quarter of 1998. If Y2K issues are discovered, the Company will evaluate
and prioritize the problems. The Company expects to coordinate any Y2K problems
with the vendors that supplied the noncompliant systems. The Company expects
that any remediation efforts would continue through mid-1999. However, there can
be no assurance that the Company's survey will identify all Y2K problems in
these systems or that the necessary corrective actions will be completed in a
timely manner.
MacroChem does not write its own application software, but depends on
third-party vendors. Therefore, the Company's survey will begin to assess the
Company's vulnerability to the Y2K problems of key third-party vendors and
service suppliers in the fourth quarter of 1998. The Company intends to
continuously identify and prioritize critical vendors and suppliers and
communicate with them about their plans and progress in addressing the Y2K
problem. The Company intends to implement a policy to exclude the use of any
vendors which are not Y2K compliant.
Based on the efforts described above, the Company currently believes
that its systems will be Y2K compliant in a timely manner. However, there can be
no assurance that all Y2K problems will be successfully identified, or that the
necessary corrective actions will be completed in a timely manner. Failure to
successfully identify and remediate such Y2K problems in a timely manner could
have a material adverse effect on the Company's results of operations, financial
position or cash flow.
The Company has not created a formal contingency plan for Y2K problems
and currently does not intend to create one. However, the Company intends to
take appropriate actions to mitigate the effects of third parties' failures to
remediate their Y2K issues and for unexpected failures in its own systems. Such
actions may include having arrangements for alternate suppliers and using manual
intervention where necessary. If it becomes necessary for the Company to take
these corrective actions, it is uncertain whether this would result in
significant interruptions of business operations or would have a material
adverse effect on the Company's results of operations, financial position or
cash flow.
As of September 30, 1998, the Company had not incurred significant
costs related to the Y2K problem, and does not expect to in the future. Overall,
the Company anticipates that incremental costs to the Company related to the Y2K
problem will not exceed $50,000, but there can be no assurance that such costs
will not be greater that anticipated.
Readers are cautioned that forward-looking statements contained in this
"Year 2000 Disclosure" section should be read in conjunction with the Company's
disclosures appearing in boldface at the end of the "Liquidity and Capital
Resources" section on page 12 of this Form 10-Q.
LIQUIDITY AND CAPITAL RESOURCES
Since inception, the primary source of funding for the Company's
operations has been the private and public sale of its securities, and to a
lesser extent, the licensing of its proprietary technology, research contracts,
and the limited sales of products and test materials.
The Company's working capital declined approximately $3.0 million from
December 31, 1997 to September 30, 1998. This reduction was primarily the result
of the Company's net loss from operations, net of non cash items, of $2.4
million, combined with $.7 million expended for the repurchase of common stock.
Until such time as the Company obtains agreements with third-party
licensees or partners to provide sufficient funding for the Company's
anticipated business activities or the Company is able to obtain funds through
the private or public sale of its securities, the Company's working capital will
be utilized to fund its activities.
Capital expenditures and patent development costs for the nine months
ended September 30, 1998 aggregated approximately $293,000. The Company expects
capital expenditures and patent development costs for the remainder of the year
to increase slightly.
The Company's long term capital requirements will depend upon numerous
factors, including the progress of the Company's research and development
programs; the resources that the Company devotes to self-funded clinical testing
of SEPA enhanced compounds; proprietary manufacturing methods and advanced
technologies; the ability of the Company to enter into additional licensing
arrangements or other strategic alliances; the ability of the Company to
manufacture products under those arrangements; and the demand for its products
or the products of its licensees or strategic partners if and when approved for
sale by regulatory authorities. In any event, substantial additional funds will
be required before the Company is able to generate revenues sufficient to
support its long term operations. There is no assurance that the Company will be
able to obtain such additional funds on favorable terms, if at all. The
Company's inability to raise sufficient funds could require it to delay, scale
back or eliminate certain research and development programs.
The Company believes that its existing cash and marketable securities
will be sufficient to meet its operating expenses and capital expenditure
requirements for at least the next twelve months. The Company's cash
requirements may vary materially from those now planned because of changes in
focus and direction of the Company's research and development programs,
competitive and technical advances, patent developments or other developments.
It is not believed that inflation will have any significant effect on the
results of the Company's operations.
THIS REPORT CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND
UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THE
RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS IN THIS REPORT AND IN
FORWARD-LOOKING STATEMENTS MADE FROM TIME TO TIME BY THE COMPANY ON THE BASIS OF
MANAGEMENT'S THEN-CURRENT EXPECTATIONS. FACTORS THAT MIGHT CAUSE SUCH A
DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO THE FOLLOWING: THE COMPANY'S HISTORY
OF OPERATING LOSSES AND NEED FOR CONTINUED WORKING CAPITAL; TECHNOLOGICAL
UNCERTAINTY RELATING TO TRANSDERMAL DRUG DELIVERY SYSTEMS AND THE EARLY STAGE OF
DEVELOPMENT OF THE COMPANY'S PROPOSED PRODUCTS; THE COMPANY'S NEED FOR
SIGNIFICANT ADDITIONAL PRODUCT DEVELOPMENT EFFORTS AND ADDITIONAL FINANCING;
UNCERTAINTIES RELATED TO CLINICAL TRIALS OF THE COMPANY'S PROPOSED PRODUCTS; THE
COMPANY'S DEPENDENCE ON THIRD PARTIES FOR COMMERCIALIZATION; NO ASSURANCE OF
LICENSE ARRANGEMENTS; THE LACK OF SUCCESS OF THE COMPANY'S PRIOR DEVELOPMENT
EFFORTS; UNCERTAINTIES RELATED TO GOVERNMENT REGULATION AND REGULATORY
APPROVALS; THE COMPANY'S DEPENDENCE ON THIRD PARTIES FOR THE FDA APPLICATION
PROCESS; THE COMPANY'S LACK OF EXPERIENCED MARKETING PERSONNEL AND DEPENDENCE ON
THIRD PARTIES FOR MARKETING AND DISTRIBUTION; THE COMPANY'S DEPENDENCE ON THIRD
PARTIES FOR MANUFACTURING; THE COMPANY'S RELIANCE ON KEY EMPLOYEES, THE LIMITED
PERSONNEL OF THE COMPANY AND ITS DEPENDENCE ON ACCESS TO SCIENTIFIC TALENT;
UNCERTAINTIES RELATING TO COMPETITION, PATENTS AND PROPRIETARY TECHNOLOGY;
UNCERTAINTIES RELATING TO RISKS OF PRODUCT LIABILITY CLAIMS, LACK OF PRODUCT
LIABILITY INSURANCE, AND EXPENSE AND DIFFICULTY OF OBTAINING ADEQUATE INSURANCE
COVERAGE; UNCERTAINTY OF PHARMACEUTICAL PRICING AND RELATED MATTERS; AND OTHER
FACTORS. ADDITIONAL INFORMATION ON THESE AND OTHER FACTORS WHICH COULD AFFECT
THE COMPANY'S ACTUAL RESULTS AND EXPERIENCE ARE INCLUDED IN THE COMPANY'S ANNUAL
REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 1997 AND, IN PARTICULAR, THE
SECTION ENTITLED "RISK FACTORS".
<PAGE>
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The following exhibits are filed herewith:
27. Financial Data Schedule
(b) No reports on Form 8-K were filed during the quarter for which this
report is filed.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
MACROCHEM CORPORATION
---------------------
(Registrant)
November 13, 1998 /S/ ALVIN J. KARLOFF
--------------------
Alvin J. Karloff
President & C.E.O.
/S/ WILLIAM P. JOHNSON
----------------------
William P. Johnson
Treasurer
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Company's balance sheet, statement of operations, statement of stockholder's
equity and statement of cash flows and is qualified in its entirety by reference
to such financial statements.
</LEGEND>
<CIK> 0000743884
<NAME> MacroChem Corporation
<MULTIPLIER> 1
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> Dec-31-1998
<PERIOD-START> Jan-1-1998
<PERIOD-END> Sep-30-1998
<EXCHANGE-RATE> 1
<CASH> 6,169,583
<SECURITIES> 15,927,391
<RECEIVABLES> 187,497
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 22,460,531
<PP&E> 1,085,291
<DEPRECIATION> 687,169
<TOTAL-ASSETS> 23,174,572
<CURRENT-LIABILITIES> 749,046
<BONDS> 0
0
0
<COMMON> 222,752
<OTHER-SE> 21,702,774
<TOTAL-LIABILITY-AND-EQUITY> 23,174,572
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 3,921
<INCOME-PRETAX> (3,039,865)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,039,865)
<EPS-PRIMARY> (0.14)
<EPS-DILUTED> (0.14)
</TABLE>
